4: Statement of changes in beneficial ownership of securities-Director Bode John B
4: Statement of changes in beneficial ownership of securities-Director DIXON WENDY L
4: Statement of changes in beneficial ownership of securities-Director FAVORITO TAMARA A
4: Statement of changes in beneficial ownership of securities-Director Calder Douglas W
4: Statement of changes in beneficial ownership of securities-Director Watton Corey Michael
4: Statement of changes in beneficial ownership of securities-Director Shih Alvin
4: Statement of changes in beneficial ownership of securities-Director Anderson Thomas
8-K: Current report
10-Q: Quarterly report
8-K: Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
DEFA14A: Others
KemPharm | 424B3: Prospectus
KemPharm | 8-K: Current report
KemPharm | EFFECT: Others
KemPharm | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
CORRESP: CORRESP
KemPharm | DEFA14A: Others
KemPharm | DEF 14A: Definitive information statements
KemPharm | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
KemPharm | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
No Data